CTOs on the Move

Virtus Pharmaceuticals

www.virtusrx.com

 
Virtus Pharmaceuticals’ mission is to be the leading specialty niche pharmaceutical company providing the highest quality products through experienced leadership, innovative approaches and outstanding customer service.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.virtusrx.com
  • 2649 Causeway Center Drive
    Tampa, FL USA 33619
  • Phone: 813.283.1344

Executives

Name Title Contact Details

Similar Companies

Stason Pharmaceuticals Inc

Stason Pharmaceuticals Inc is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Septodent

Septodent is a Cambridge, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avante HS

Avante is a single source provider of surgical, diagnostic imaging and radiation oncology equipment. Sales, service, repair, parts, installation.

Sunrise Treatment Center

We are a substance abuse treatment program focusing primarily on opioid use disorders. We have locations in Cincinnati, Forest Park, Middletown, and Dayton. Services include individual and group counseling, urinalysis, case management, and cri...

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.